Limit of Detection: The Smallest Signal a Molecular Assay Can Call
Every molecular assay has a floor below which it cannot reliably distinguish a real variant from background noise. This limit of detection is a defined performance characteristic, and it is the key number for understanding what a negative result does and does not mean.
Quick Answer
Every molecular assay has a floor below which it cannot reliably distinguish a real variant from background noise. This limit of detection is a defined performance characteristic, and it is the key number for understanding what a negative result does and does not mean.
What the Limit of Detection Is
The limit of detection is the lowest amount of a target, usually expressed as a variant allele fraction, that the assay can detect with a stated probability, commonly 95 percent, while keeping false positives acceptably low.
It is established during validation by testing dilution series of known-positive material and is a property of the assay for a given variant type and input amount.
What Sets It
Key factors are sequencing depth (more reads distinguish a true low-level signal from error), the background error rate of the chemistry and bioinformatics, the amount and quality of input DNA, and the variant type.
Point mutations generally have the lowest limits of detection; insertions, deletions, copy-number changes and fusions are harder and have higher (worse) limits.
Tissue vs Blood
Standard tumour tissue panels often have limits of detection around 2 to 5 percent variant allele fraction. Specialised circulating tumour DNA assays push far lower, to 0.1 percent or below, using error correction and by tracking many variants together.
Ultra-sensitive residual-disease assays achieve their sensitivity partly by being personalised to a known set of tumour mutations rather than searching broadly.
Why It Governs Negative Results
If a mutation is present at 1 percent and the assay's limit of detection is 5 percent, the assay will report negative even though the mutation is there. The negative is accurate for the assay but not for the tumour.
This is why a clinically expected mutation that is not found should be reconsidered in light of sample purity and the assay's limit of detection before concluding true absence.
Interpretation Notes
A report should state the assay's limit of detection, ideally by variant type. Treat a negative result as ruling out the variant only above that threshold.
For low-tumour-content samples or blood-based tests, the effective sensitivity for a specific case can be worse than the headline limit of detection.
Key Takeaways
- ·Limit of detection is the lowest variant fraction an assay reliably calls, set during validation.
- ·Depth, error rate, input quality and variant type all influence it.
- ·Tissue panels sit around 2 to 5 percent; specialised ctDNA assays reach 0.1 percent or lower.
- ·A negative result only excludes the variant above the assay's limit of detection.
Put these genes in pathway context
Frequently asked questions
What is the key idea in Limit of Detection: The Smallest Signal a Molecular Assay Can Call?
Every molecular assay has a floor below which it cannot reliably distinguish a real variant from background noise. This limit of detection is a defined performance characteristic, and it is the key number for understanding what a negative result does and does not mean.
What should be kept with the result or mechanism?
Depth, error rate, input quality and variant type all influence it. Tissue panels sit around 2 to 5 percent; specialised ctDNA assays reach 0.1 percent or lower. A negative result only excludes the variant above the assay's limit of detection.
References
- 1Guidelines for Validation of Next-Generation Sequencing-Based Oncology Panels. Journal of Molecular Diagnostics, 2017. PubMed
- 2Enhanced detection of minimal residual disease by targeted sequencing of phased variants in circulating tumor DNA. Nature Biotechnology, 2021. PubMed
- 3Somatic mutation panels: time to clear their names. Cancer Genetics, 2019. PubMed
- 4Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors. Archives of Pathology & Laboratory Medicine, 2018. PubMed
Continue Reading
Biomarker Assay Validation: Why the Test Behind a Result Matters
3 min read
Molecular Residual Disease: Using ctDNA to Detect Cancer That Imaging Cannot
3 min read
Tumour Purity and Sequencing: How Much Cancer Is in the Sample
3 min read
Variant Allele Fraction: What the Percentage on a Report Means
3 min read
Confirming Sequencing Results: When Is Orthogonal Testing Needed
3 min read
EGFR C797S: What This Resistance Alteration Means
2 min read
Choose your next research step
Move from this explanation into a gene profile, a pathway map, or the next evidence update.
EGFR has 1000+ trials currently recruiting on ClinicalTrials.gov. The GeneAnalyses digest summarises the new and changed ones each day.